Results: 10
Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 811, doi. 10.1007/s40265-022-01720-4
- By:
- Publication type:
- Article
Correction to: Daridorexant: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Pacritinib: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 831, doi. 10.1007/s40265-022-01718-y
- By:
- Publication type:
- Article
New Drug Delivery Systems Developed for Brain Targeting.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 749, doi. 10.1007/s40265-022-01717-z
- By:
- Publication type:
- Article
Correction to: Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Lupus Nephritis: Improving Treatment Options.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 735, doi. 10.1007/s40265-022-01715-1
- By:
- Publication type:
- Article
Faricimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 825, doi. 10.1007/s40265-022-01713-3
- By:
- Publication type:
- Article
Sutimlimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 817, doi. 10.1007/s40265-022-01711-5
- By:
- Publication type:
- Article
Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 793, doi. 10.1007/s40265-022-01707-1
- By:
- Publication type:
- Article
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
- Published in:
- Drugs, 2022, v. 82, n. 7, p. 719, doi. 10.1007/s40265-022-01703-5
- By:
- Publication type:
- Article